Analysts await Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

They expect $-0.12 EPS, down 50% or $0.06 from last year’s $-0.06 per share.

At the moment 2 analysts are watching Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), 0 rate it “Buy”, 2 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

The biggest institutional shareholders in Titan Pharmaceuticals, Inc. include Broadfin Capital, LLC which owns 761 K million shares in the company valued at $3.38 million. Vanguard Group Inc is the second biggest holder with 160 K million shares currently valued at 563.18 K million whilst Fidelity Management & Research Company has 76 K million shares valued at 268.51 K million.

Total shares held by institutions as of the most recent company filings are 962,399 with a reported 0 bought and 0 sold. These holdings make up 4.8% of the company’s outstanding shares.

Currently insiders hold 864,378 shares in the business which makes up 4.31% of shares. The biggest holder currently is Joachim Friedrich Kapp,M.D.,PhD who owns 546,339 shares (2.72% of those outstanding), whilst Dr. Marc Rubin,M.D. holds 156,317 (0.78% of shares outstanding) and Sunil Bhonsle holds 125,578 (0.63% of shares outstanding).

The stock increased 2.16% or $0.08 during the last trading session, hitting $4.06. Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has risen 7.39% over the past 6 months and is uptrending.